Dysregulation of MiR-21, MiR-221 and MiR-451 During Neoadjuvant Treatment of Breast Cancer: A Prospective Study

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2025 Jan 8

PMID 39766287

Authors

Carine Bispo Patury

Brenda Luanny Maia Santos

Anna Lucia Carvalho Matos

Jose Slabi

Luciene Cristina Campos Gastalho

Carla Martins Kaneto

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is highly heterogeneous disease in which different responses are observed to the same treatment for different subtypes and extents of similar diseases. Considering this scenario, the search for tumor biomarkers is indispensable, with current evidence suggesting that circulating microRNAs are viable biomarkers. This study evaluated the expression of miR-21, miR-221, miR-195, and miR-451 in patients with breast cancer undergoing neoadjuvant treatment at oncology outpatient facilities in Brazil.

Methods: We conducted a prospective and observational study in which blood samples were collected for microRNA expression analysis, comparing control and breast cancer patients who were candidates for neoadjuvant treatment groups. The expression of microRNAs was investigated by qRT-PCR method. For parametric data analysis, one-way ANOVA with Tukey's post hoc test was used.

Results: Thirty-three participants (all female) were included in the control group and twenty-seven participants were included in the study group. The non-special subtype of breast cancer was found in 96% of the study group participants; 88.9% were locally advanced tumors (T3, T4), 40.7% were luminal tumors, 33.3% were HER-2-positive, and 26% were triple negative tumors. Expression analysis of microRNAs during neoadjuvant treatment, using miR-16 as a normalizer, showed higher expression levels of miR-21 and miR-221 at the end of treatment, and high expression levels for miR-451 were also observed at the beginning of treatment.

Conclusion: This is the first study that evaluates the expression of microRNAs in the context of neoadjuvant treatment of breast cancer in the Brazilian population. Our results suggest that there is a deregulation of miR-21, miR-221, and miR-451 during neoadjuvant treatment in these patients.

References

Dornelles Rosa D, Bines J, Werutsky G, Barrios C, Cronemberger E, Queiroz G . The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115). Breast Cancer Res Treat. 2020; 183(3):749-757. DOI: 10.1007/s10549-020-05831-y. View

Yadav P, Mirza M, Nandi K, Jain S, Kaza R, Khurana N . Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients. Tumour Biol. 2016; 37(11):15275-15282. DOI: 10.1007/s13277-016-5361-y. View

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

Khalighfard S, Alizadeh A, Irani S, Omranipour R . Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Sci Rep. 2018; 8(1):17981. PMC: 6299272. DOI: 10.1038/s41598-018-36321-3. View

Mangone L, Mancuso P, Tagliabue G, Filiberti R, Carrozzi G, Iacovacci S . Neoadjuvant therapy for breast cancer. Tumori. 2019; 105(6):488-493. DOI: 10.1177/0300891619869505. View

von Minckwitz G, Huang C, Mano M, Loibl S, Mamounas E, Untch M . Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2018; 380(7):617-628. DOI: 10.1056/NEJMoa1814017. View

Magalhaes Filho M, Aguiar Jr P, Neves M, de Lima Lopes Jr G, Del Giglio A . Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer. Einstein (Sao Paulo). 2022; 20:eGS6655. PMC: 9071260. DOI: 10.31744/einstein_journal/2022GS6655. View

Dluzen D, Noren Hooten N, Zhang Y, Kim Y, Glover F, Tajuddin S . Racial differences in microRNA and gene expression in hypertensive women. Sci Rep. 2016; 6:35815. PMC: 5078799. DOI: 10.1038/srep35815. View

Motawi T, Hamid Sadik N, Shaker O, El Masry M, Mohareb F . Study of microRNAs-21/221 as potential breast cancer biomarkers in Egyptian women. Gene. 2016; 590(2):210-9. DOI: 10.1016/j.gene.2016.01.042. View

10.

Boughey J, McCall L, Ballman K, Mittendorf E, Ahrendt G, Wilke L . Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014; 260(4):608-14. PMC: 4159769. DOI: 10.1097/SLA.0000000000000924. View

11.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

12.

Meerson A, Eliraz Y, Yehuda H, Knight B, Crundwell M, Ferguson D . Obesity impacts the regulation of miR-10b and its targets in primary breast tumors. BMC Cancer. 2019; 19(1):86. PMC: 6339293. DOI: 10.1186/s12885-019-5300-6. View

13.

Heneghan H, Miller N, Lowery A, Sweeney K, Newell J, Kerin M . Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251(3):499-505. DOI: 10.1097/SLA.0b013e3181cc939f. View

14.

Liu B, Su F, Lv X, Zhang W, Shang X, Zhang Y . Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab. Cancer Chemother Pharmacol. 2019; 84(5):1039-1049. DOI: 10.1007/s00280-019-03937-9. View

15.

Mamtani A, Barrio A, King T, Van Zee K, Plitas G, Pilewskie M . How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Ann Surg Oncol. 2016; 23(11):3467-3474. PMC: 5070651. DOI: 10.1245/s10434-016-5246-8. View

16.

Iorio M, Casalini P, Piovan C, Braccioli L, Tagliabue E . Breast cancer and microRNAs: therapeutic impact. Breast. 2011; 20 Suppl 3:S63-70. DOI: 10.1016/S0960-9776(11)70297-1. View

17.

Tiberio P, Gaudio M, Belloni S, Pindilli S, Benvenuti C, Jacobs F . Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis. Cancers (Basel). 2023; 15(13). PMC: 10340268. DOI: 10.3390/cancers15133424. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Zhao R, Wu J, Jia W, Gong C, Yu F, Ren Z . Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie. 2011; 34(12):675-80. DOI: 10.1159/000334552. View

20.

de Oliveira S, Souza B, Sa Barreto E, Kaneto C, Neto H, Azevedo C . Reduction of galectin-3 expression and liver fibrosis after cell therapy in a mouse model of cirrhosis. Cytotherapy. 2011; 14(3):339-49. DOI: 10.3109/14653249.2011.637668. View